These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7830002)

  • 1. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles.
    Jacks T; Hickey G; Judith F; Taylor J; Chen H; Krupa D; Feeney W; Schoen W; Ok D; Fisher M
    J Endocrinol; 1994 Nov; 143(2):399-406. PubMed ID: 7830002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles.
    Hickey G; Jacks T; Judith F; Taylor J; Schoen WR; Krupa D; Cunningham P; Clark J; Smith RG
    Endocrinology; 1994 Feb; 134(2):695-701. PubMed ID: 8299565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
    Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
    Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine.
    Chang CH; Rickes EL; McGuire L; Frazier E; Chen H; Barakat K; Nargund R; Patchett A; Smith RG; Hickey GJ
    Endocrinology; 1996 Nov; 137(11):4851-6. PubMed ID: 8895356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
    Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
    J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
    Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
    Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585.
    Fairhall KM; Mynett A; Smith RG; Robinson IC
    J Endocrinol; 1995 Jun; 145(3):417-26. PubMed ID: 7636426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.
    Hayashi S; Okimura Y; Yagi H; Uchiyama T; Takeshima Y; Shakutsui S; Oohashi S; Bowers CY; Chihara K
    Endocrinol Jpn; 1991 Feb; 38(1):15-21. PubMed ID: 1915110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
    Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
    Gertz BJ; Barrett JS; Eisenhandler R; Krupa DA; Wittreich JM; Seibold JR; Schneider SH
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1393-7. PubMed ID: 8077339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracerebroventricular and intravenous administration of growth hormone secretagogue L-692,585, somatostatin, neuropeptide Y and galanin in pig: dose-dependent effects on growth hormone secretion.
    Cho SJ; Lee JS; Mathias ED; Chang C; Hickey GJ; Lkhagvadorj S; Anderson LL
    Comp Biochem Physiol C Toxicol Pharmacol; 2010 May; 151(4):412-9. PubMed ID: 20074661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study.
    Chapman IM; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2874-80. PubMed ID: 8768844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of a novel nonpeptidyl growth hormone secretagogue, L-700,653, in swine.
    Chang CH; Rickes EL; Marsilio F; McGuire L; Cosgrove S; Taylor J; Chen H; Feighner S; Clark JN; De Vita R
    Endocrinology; 1995 Mar; 136(3):1065-71. PubMed ID: 7867560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel non-peptidyl growth hormone secretagogue.
    Cheng K; Chan WW; Butler B; Wei L; Smith RG
    Horm Res; 1993; 40(1-3):109-15. PubMed ID: 7905455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585.
    Hickey GJ; Drisko J; Faidley T; Chang C; Anderson LL; Nicolich S; McGuire L; Rickes E; Krupa D; Feeney W; Friscino B; Cunningham P; Frazier E; Chen H; Laroque P; Smith RG
    J Endocrinol; 1996 Feb; 148(2):371-80. PubMed ID: 8699151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.
    Pihoker C; Badger TM; Reynolds GA; Bowers CY
    J Endocrinol; 1997 Oct; 155(1):79-86. PubMed ID: 9390009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
    Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue.
    Cheng K; Chan WW; Butler B; Wei L; Schoen WR; Wyvratt MJ; Fisher MH; Smith RG
    Endocrinology; 1993 Jun; 132(6):2729-31. PubMed ID: 8389289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.